| Gene symbol | CD19 | Synonyms | B4, CVID3 | Type of gene | protein-coding |
| Chromosome | 16 | Map location | 16p11.2 | dbXrefs | |
| Description | CD19 molecule | ||||
| GTO ID | GTC3453 |
| Trial ID | NCT05873712 |
| Disease | Chronic Lymphocytic Leukemia | Non-Hodgkin's Lymphoma | Diffuse Large B-Cell Lymphoma |
| Altered gene | CD19 |
| Therapeutic/Target gene | Target gene |
| Therapy | CAR-T cell |
| Treatment | Breyanzi|Lisocabtagene maraleucel|liso-cel|JCAR017 |
| Co-treatment | zanubrutinib |
| Location approved | US, Japan, EU, Switzerland, UK, Canada |
| Generation | 2nd |
| Phase | Phase2 |
| Recruitment status | Recruiting |
| Title | Zanubrutinib and Lisocabtagene Maraleucel for the Treatment of Richter's Syndrome |
| Year | 2023 |
| Country | United States |
| Company sponsor | Adam Kittai |
| Other ID(s) | OSU-22157|NCI-2023-03669 |
| Cohort 1 | |||||||||
|
|||||||||